Janssen G M C GMC

Show results for

Proteomics (4)
Unknown (2)

Organisms

Alphavirus (3)
Archaea (3)
Bacteria (3)
Betaherpesvirinae (3)
Borrelia (3)
Botrytis cinerea (3)
Candida albicans (3)
Clostridium perfringens (3)
Eukaryota (3)
Fungi (3)
Hepatitis B virus (3)
Human betaherpesvirus 5 (3)
Influenza A virus (3)
Influenza C virus (3)
Japanese encephalitis virus group (3)
Mammarenavirus (3)
Miscanthus x giganteus (3)
Mycobacterium tuberculosis (3)
Orthoflavivirus (3)
Panicum virgatum (3)
Pseudomonas aeruginosa (3)
Rattus (3)
Saccharomyces cerevisiae (3)
Schizosaccharomyces (3)
Schizosaccharomyces pombe (3)
Severe acute respiratory syndrome coronavirus 2 (3)
Staphylococcus aureus (3)
Streptococcus pneumoniae (3)
Tripsacum dactyloides (3)
Viruses (3)

Repository

pride (3)
MassIVE (1)

Tissue

Cell culture (2)
Neural retina (1)
Stem cell (1)

Disease

Acute leukemia (1)

Technology Type

Mass Spectrometry (3)
Shotgun proteomics (3)
MSE (1)
Top-down proteomics (1)

Instrument Platform

Orbitrap Fusion Lumos (1)

Publication Date

2021 (2)
2020 (1)
2023 (1)

Release Date

2025 (1)
2022 (1)

Lab affiliation

Center for Proteomics and Metabolomics; Leiden University Medical Center; 2333 ZA Leiden, The Netherlands (1)
Head Proteomics Group Leiden University Medical Center Center for Proteomics and Metabolomics (1)
Immune monitoring lab Department of Immunohematology and Blood transfusion Leiden University Medical Center (LUMC) The Netherlands (1)

Previous page
1 / 1
You're on page 1
Next page

Sort by:

Relevance

Page size

Immunogenicity of SARS-CoV-2 vaccines in patients with breast cancer.

Not available

S-EPMC9425892 | biostudies-literature

POLR2M-mediated paused transcription silences tumor suppressor MIR139 in MLL-AF9 AML

MIR139 is a critical tumor suppressor and commonly silenced in human cancer, including acute myeloid leukemia (AML). Here, we found that depletion of identified MIR139 targets affects AML outgrowth. We unraveled the mechanism of MIR139 gene inactivation in AML expressing the Mixed-Lineage Leukemia (...

ORGANISM(S): Mus musculus (Mouse)

2021-11-11 | PXD022488 | Pride

Site-specific glycosylation mapping of Fc gamma receptor IIIb from neutrophils of individual healthy donors

The uploaded dateset corresponds to MS1 and MS2 spectra obtained for Fc gamma receptor IIIb isolated from neutrophils of individual healthy donors. They represent NA1/NA2, NA2/NA2, NA2/NA2 allotype respectively. Based on the data, the targeted analysis of the N-glycosylation has been performed for t...

ORGANISM(S): Homo Sapiens (ncbitaxon:9606)

2020-08-05 | MSV000085913 | MassIVE

Retinal proteomics of a mouse model of dystroglycanopathies shows changes in different photoreceptor regions

Mutations in the POMT1 gene, encoding a protein O-mannosyltransferase essential for alpha-dystroglycan (α-DG) glycosylation, are frequently observed in a group of rare congenital muscular dystrophies, collectively known as dystroglycanopathies. However, it is hitherto unclear whether the effects se...

ORGANISM(S): Mus musculus (Mouse)

2021-09-10 | PXD023704 | Pride

Mouse model Dystroglycanopathies Photoreceptor

Evaluation of proteomics strategies for low cell numbers: SP3- and C18-based protocols combined with five cell lysis methods

New advances in the transcriptomics and flow cytometry fields have allowed the discovery of new immune cell subsets. However, most of them are extremely small populations, hampering their analysis using mass spectrometry strategies since currently these procedures are not highly efficient in small s...

ORGANISM(S): Homo sapiens (Human)

2023-02-09 | PXD018872 | Pride

Human Ht-29 C18 Macrophages Low cell number Sp3 Thp-1 Small populations

Definitions of clinical study outcome measures for cardiovascular diseases: the European Unified Registries for Heart Care Evaluation and Randomized Trials (EuroHeart).